ERLANGER Home
MyErlangerHealth HealthLink Plus For Vendors For the Media Physician Relations and Recruitment
975 East Third Street
Chattanooga, TN 37403
423-778-7000
Children's Hospital at Erlanger Erlanger Baroness Campus Erlanger Bledsoe Campus Erlanger East Campus Erlanger North Campus UT Erlanger Physicians Group





Online Prereg
Register for a Class or Event
New Foundations Page
Print   Email

Gastrointestional

Adjuvant (After Surgey) Colon Cancer Trials

C80702                             Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. (IRB#: 10-113)

NCT #: NCT01150045        Phase: Phase III

Purpose:This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

Drugs possibly given:
Celecoxib
Fluorouracil
Leucovorin calcium
Oxaliplatin
Placebo

Please view complete information about this trial at: http://www.clinicaltrial.gov/ct2/show/NCT01150045?term=CALGB80702&rank=1

S1115                             Principal Investigator: Larry Schlabach, MD

                                             Co-Investigator: John McCravey, MD and Matt Graham, MD

Title:  Randomized Phase II Clinical Trial ofAZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy (IRB#: 13-007)

NCT #: NCT01658943       Phase: Phase II

Purpose: This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to mFOLFOX therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy. Selumetinib and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet know whether selumetinib and Akt inhibitor MK2206 are more effective than oxaliplatin and fluorouracil in treating patients with metastatic pancreatic cancer.

Drugs possibly given:
Akt inhibitor MK2206                                                                                                                                                                                                                                                                
FOLFOX (FOLinic acid-Fluoruracil-OXaliplatin)
Selumetinib

Please view complete information about this trial at: http://www.clinicaltrials.gov/ct2/show/NCT01658943?term=S1115&rank=1